Eligibility

1 forms
  1. StudyEvent: Eligibility
    1. Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Inclusion Criteria
age
Item
18 Years and older
boolean
Scalp psoriasis
Item
Scalp psoriasis amenable to topical treatment with a maximum of 100 g of study medication per week
boolean
Psoriasis vulgaris
Item
Clinical signs of psoriasis vulgaris on trunk and/or limbs, or earlier diagnosed with psoriasis vulgaris on trunk and/or limbs
boolean
Extension
Item
Extent of scalp psoriasis involving more than 10% of the total scalp area
boolean
Disease severity
Item
Disease severity on the scalp graded as Moderate, Severe or Very Severe according to the Investigator's Global Assessment of disease severity
boolean
Item Group
Exclusion Criteria
PUVA or Grenz ray Radiation therapy
Item
PUVA or Grenz ray therapy anywhere on the patient within 28 days prior to randomisation
boolean
UVB therapy
Item
UVB therapy anywhere on the patient within 14 days prior to randomisation
boolean
Biologicals
Item
Systemic use of biological treatments, whether marketed or not, directed against or with a potential effect on, scalp psoriasis (e.g., alefacept, efalizumab, etanercept, infliximab) within 6 months prior to randomisaiton
boolean
Systemic treatment with effect on scalp psoriasis
Item
Systemic treatments with a potential effect on scalp psoriasis vulgaris (e.g., corticosteroids, retinoids, immunosuppressants) within 28 days prior to randomisation
boolean
topical treatment for scalp
Item
Any topical treatment for scalp psoriasis or any other skin disease on the scalp (excluding medicated shampoos, emollients and hair conditioners) within 14 days prior to randomisaiton
boolean
Topical treatment with very potent WHO group IV corticosteroids
Item
Topical treatment for other skin disorders with very potent WHO group IV corticosteroids within 14 days prior to randomisation
boolean
Planned initiation of, or changes in dose of concomitant medication that could affect scalp psoriasis
Item
Planned initiation of, or changes in dose of concomitant medication that could affect scalp psoriasis (e.g., beta blockers, antimalarial drugs, lithium) during the study
boolean
guttate, pustular, exfoliative or erythrodermic psoriasis
Item
Current diagnosis of guttate, pustular, exfoliative or erythrodermic psoriasis
boolean
viral lesions, fungal and bacterial skin infections, parasitic infections and atrophic skin on the scalp
Item
Patients with any of the following conditions present on the scalp area: viral lesions, fungal and bacterial skin infections, parasitic infections and atrophic skin
boolean
renal insufficiency or severe hepatic disorders
Item
Known or suspected severe renal insufficiency or severe hepatic disorders
boolean
clinically significant hypercalcaemia
Item
Patiens with history/signs/symptoms suggestive of an abnormality of calcium homeostasis associated with clinically significant hypercalcaemia
boolean
contraception
Item
Trial subjects should be using an adequate method of contraception
boolean
Item Group
Medical Concepts
Age
Item
Age
string
C0001779 (UMLS CUI)
102518004 (SNOMED CT 2010_0731)
Diagnosis
Item
Diagnosis
string
C0011900 (UMLS CUI)
439401001 (SNOMED CT 2010_0731)
MTHU008876 (LOINC Version 232)
Psoriasis
Item
Psoriasis
string
C0033860 (UMLS CUI)
9014002 (SNOMED CT 2010_0731)
10037153 (MedDRA 13.1)
L40 (ICD-10-CM Version 2010)
Scalp psoriasis
Item
Scalp psoriasis
string
C0406326 (UMLS CUI)
238608008 (SNOMED CT 2010_0731)
10037157 (MedDRA 13.1)
Psoriasis vulgaris
Item
Psoriasis vulgaris
string
C0263361 (UMLS CUI)
10050576 (MedDRA 13.1)
L40.0 (ICD-10-CM Version 2010)
Extension
Item
Extension
string
C0231448 (UMLS CUI)
255536004 (SNOMED CT 2010_0731)
MTHU010348 (LOINC Version 232)
Severity Code
Item
Disease severity
string
CL425496 (UMLS CUI)
Therapy
Item
treatment
string
C0039798 (UMLS CUI)
Radiation
Item
radiation
string
C0851346 (UMLS CUI)
82107009 (SNOMED CT 2010_0731)
MTHU026213 (LOINC Version 232)
PUVA
Item
PUVA
string
C0853073 (UMLS CUI)
10037580 (MedDRA 13.1)
Grenz ray
Item
Rays, Grenz
string
C0018233 (UMLS CUI)
52250000 (SNOMED CT 2010_0731)
UVB
Item
Ultraviolet B Radiation
string
C0564461 (UMLS CUI)
286632006 (SNOMED CT 2010_0731)
Pharmaceutical Preparations
Item
Medication
string
C0013227 (UMLS CUI)
Biological Products
Item
Biological agent
string
C0005522 (UMLS CUI)
418980009 (SNOMED CT 2010_0731)
topical treatment
Item
Skin care: topical treatments
string
C0150349 (UMLS CUI)
386439008 (SNOMED CT 2010_0731)
corticosteroids
Item
Therapeutic Corticosteroid
string
C0001617 (UMLS CUI)
79440004 (SNOMED CT 2010_0731)
guttate psoriasis
Item
Psoriasis guttata
string
C0343052 (UMLS CUI)
37042000 (SNOMED CT 2010_0731)
L40.4 (ICD-10-CM Version 2010)
pustular psoriasis
Item
pustular psoriasis
string
C0152081 (UMLS CUI)
200973000 (SNOMED CT 2010_0731)
10037159 (MedDRA 13.1)
erythrodermic psoriasis
Item
exfoliative psoriasis
string
C0748052 (UMLS CUI)
200977004 (SNOMED CT 2010_0731)
10015278 (MedDRA 13.1)
Infection
Item
Infection
string
C0021311 (UMLS CUI)
257551009 (SNOMED CT 2010_0731)
10021789 (MedDRA 13.1)
atrophic skin
Item
Atrophic condition of skin
string
C0151514 (UMLS CUI)
400190005 (SNOMED CT 2010_0731)
10040799 (MedDRA 13.1)
L90.9 (ICD-10-CM Version 2010)
E13714 (CTCAE Version 4.03)
renal insufficiency
Item
Renal Insufficiency
string
C1565489 (UMLS CUI)
10022467 (MedDRA 13.1)
hepatic disorders
Item
Hepatic disorders (SMQ)
string
C1869009 (UMLS CUI)
20000005 (MedDRA 13.1)
hypercalcaemia
Item
Hypercalcemia
string
C0020437 (UMLS CUI)
66931009 (SNOMED CT 2010_0731)
10020583 (MedDRA 13.1)
E83.52 (ICD-10-CM Version 2010)
275.42 (ICD-9-CM Version 2011)
E12270 (CTCAE Version 4.03)
Contraception
Item
Contraception
string
C0700589 (UMLS CUI)
146680009 (SNOMED CT 2010_0731)
10010808 (MedDRA 13.1)
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial